Last Posted: Aug 02, 2018
- Effect of Apolipoprotein E ?4 Carrier Status on Cognitive Response to Acetylcholinesterase Inhibitors in Patients with Alzheimer's Disease: A Systematic Review and Meta-Analysis.
Cheng Ying-Chih et al. Dementia and geriatric cognitive disorders 2018 Jul 45(5-6) 335-352 - What Personal Genome Testing Can and Can't Do-The limitations of personal genome service testing
M Shermer, Scientific American, August 2018 - Effect of Apolipoprotein E ɛ4 Carrier Status on Cognitive Response to Acetylcholinesterase Inhibitors in Patients with Alzheimer's Disease: A Systematic Review and Meta-Analysis.
Cheng Ying-Chih et al. Dementia and geriatric cognitive disorders 2018 Jul 45(5-6) 335-352 - Advances in the discovery of genetic risk factors for complex forms of neurodegenerative disorders: contemporary approaches, success, challenges and prospects.
Kumar Sumeet et al. Journal of genetics 2018 Jul 97(3) 625-648 - Precision Medicine for Alzheimer's Disease Prevention.
Berkowitz Cara L et al. Healthcare (Basel, Switzerland) 2018 Jul 6(3) - Whole-exome sequencing in 20,197 persons for rare variants in Alzheimer's disease.
Raghavan Neha S et al. Annals of clinical and translational neurology 2018 Jul 5(7) 832-842 - A decade in psychiatric GWAS research.
Horwitz Tanya et al. Molecular psychiatry 2018 Jun - Alzheimer's Disease and Frontotemporal Dementia: The Current State of Genetics and Genetic Testing Since the Advent of Next-Generation Sequencing.
Goldman Jill S et al. Molecular diagnosis & therapy 2018 Jul - Editorial: Turning Point towards Blood Biomarker-Guided Targeted Therapy for Precision Medicine in Alzheimer's disease.
Hampel H et al. The journal of prevention of Alzheimer's disease 2018 5(3) 160-164 - The INCLUDE Project Research Plan- (INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndrome)
.png)
No hay comentarios:
Publicar un comentario